Meeting
2013 ASCO Annual Meeting
Safety of trastuzumab in HER2-positive primary breast cancer in Japan: Initial safety report for the large-scale cohort study (JBCRG C-01).
Authors
Naohito Yamamoto
Chiba Cancer Center, Chiba, Japan
Naohito Yamamoto , Hiroyasu Yamashiro , Hiroji Iwata , Norikazu Masuda , Shoichiro Ohtani , Masato Takahashi , Kosuke Yamazaki , Makoto Kato , Shinji Ohno , Katsumasa Kuroi , Kazuhiko Yamagami , Takashi Morimoto , Yoshie Hasegawa , Toshimi Takano , Takayuki Kadoya , Mitsuchika Hosoda , Hajime Abe , Satoshi Morita , Shinji Yasuno , Masakazu Toi
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer - HER2/ER
Track
Breast Cancer
Sub Track
HER2+
Clinical Trial Registration Number
000002737
Citation
J Clin Oncol 31, 2013 (suppl; abstr 613)
DOI
10.1200/jco.2013.31.15_suppl.613
Abstract #
613
Poster Bd #
10D
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
Trastuzumab-related subclinical cardiotoxicity in patients with early stage HER2-positive breast cancer: A retrospective single-center cohort study.
First Author: Olexiy Aseyev
Poster
2021 ASCO Annual Meeting
Cardiac safety of dual anti-HER2 blockade with pertuzumab plus trastuzumab (P+T) in the APHINITY trial.
First Author: Evandro de Azambuja
Poster
2015 Breast Cancer Symposium
Trastuzumab-induced cardiotoxicity in Uruguayan HER2-positive breast cancer patients.
First Author: Andrea Schiavone
Poster
2014 ASCO Annual Meeting
Long-term cardiac safety analysis of NCCTG (Alliance) N9831 adjuvant trastuzumab (H) trial.
First Author: Pooja Prem Advani